Adverse effects of acebutolol in chronic stable angina: drug-induced positive antinuclear antibody.
Acebutolol, a cardioselective beta-adrenergic blocking agent, was administered for 48 weeks to 11 patients with chronic stable angina in a single-blind trial for determining efficacy and safety. As expected, beta-adrenergic blockade reduced angina frequency and improved exercise performance (p less than 0.001). Three patients developed an antinuclear antibody (ANA) titer, and in two patients a low titer present during placebo treatment increased fourfold. Two patients had joint symptoms probably related to acebutolol administration. Readministration of acebutolol after the ANA returned to negative resulted in a significant rise in ANA titer in two patients tested. The other nine patients tolerated long-term acebutolol therapy without significant side effects.
D000070:Acebutolol / Q000009:adverse effects*; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy* / Q000276:immunology; D000974:Antibodies, Antinuclear / Q000032:analysis*; D001327:Autoimmune Diseases / Q000139:chemically induced; D002908:Chronic Disease; D006801:Humans; D008168:Lung / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion
D000974:Antibodies, Antinuclear; D000070:Acebutolol